Ram Aiyar

Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA.

FlowMetric, Inc. provides flow cytometry and cell sorting services. It serves partners in multiple fields including biotechnology, small and large cap pharmaceuticals, hospitals and academic institutions. The firm provides flow cytometry, pre-clinical, pre-clinical toxicology and safety, clinical, cell sorting, monoclonal antibody production, and agri-food services. The company was founded by Renold Capocasale in 2010 and is headquartered in Doylestown, PA.

Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco.

Part of Vaccitech Plc, Avidea Technologies, Inc. is a biotechnology company based in Baltimore, MD. Avidea is advancing the next generation of safer and more effective T cell immunotherapies for treating cancer, infections, and autoimmune diseases. The company's precision immunotherapies are enabled by polymer-drug conjugate technologies, which are purpose-built to address the need for improved T cell and antibody-based immunotherapies. The company was founded by Geoffrey Lynn and Andrew Ishizuka, and Geoffrey Lynn has been the CEO since incorporation. Avidea was acquired by Vaccitech Plc on December 13, 2021 for $40 million.